JP2005516606A - 哺乳動物のサイトカイン；関連する試薬の使用 - Google Patents

哺乳動物のサイトカイン；関連する試薬の使用 Download PDF

Info

Publication number
JP2005516606A
JP2005516606A JP2003565411A JP2003565411A JP2005516606A JP 2005516606 A JP2005516606 A JP 2005516606A JP 2003565411 A JP2003565411 A JP 2003565411A JP 2003565411 A JP2003565411 A JP 2003565411A JP 2005516606 A JP2005516606 A JP 2005516606A
Authority
JP
Japan
Prior art keywords
tslp
cells
seq
cell
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516606A5 (enExample
Inventor
ウォル マルフィ， レン デ
ヨン−ジュン リウ，
マレハリ エル． ナガラクシュミ，
バジル ソウムリ，
ノリヒコ ワタナベ，
ウェイ ユアン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27734298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005516606(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005516606A publication Critical patent/JP2005516606A/ja
Publication of JP2005516606A5 publication Critical patent/JP2005516606A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2003565411A 2002-02-01 2003-01-30 哺乳動物のサイトカイン；関連する試薬の使用 Pending JP2005516606A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35350902P 2002-02-01 2002-02-01
PCT/US2003/002758 WO2003065985A2 (en) 2002-02-01 2003-01-30 Uses of mammalian cytokine; related reagents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009060287A Division JP5519946B2 (ja) 2002-02-01 2009-03-12 哺乳動物のサイトカイン；関連する試薬の使用

Publications (2)

Publication Number Publication Date
JP2005516606A true JP2005516606A (ja) 2005-06-09
JP2005516606A5 JP2005516606A5 (enExample) 2006-03-02

Family

ID=27734298

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003565411A Pending JP2005516606A (ja) 2002-02-01 2003-01-30 哺乳動物のサイトカイン；関連する試薬の使用
JP2009060287A Expired - Lifetime JP5519946B2 (ja) 2002-02-01 2009-03-12 哺乳動物のサイトカイン；関連する試薬の使用
JP2012138672A Pending JP2012184259A (ja) 2002-02-01 2012-06-20 哺乳動物のサイトカイン；関連する試薬の使用
JP2014103683A Pending JP2014156478A (ja) 2002-02-01 2014-05-19 哺乳動物のサイトカイン；関連する試薬の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009060287A Expired - Lifetime JP5519946B2 (ja) 2002-02-01 2009-03-12 哺乳動物のサイトカイン；関連する試薬の使用
JP2012138672A Pending JP2012184259A (ja) 2002-02-01 2012-06-20 哺乳動物のサイトカイン；関連する試薬の使用
JP2014103683A Pending JP2014156478A (ja) 2002-02-01 2014-05-19 哺乳動物のサイトカイン；関連する試薬の使用

Country Status (11)

Country Link
US (5) US20030186875A1 (enExample)
EP (3) EP1487865A4 (enExample)
JP (4) JP2005516606A (enExample)
AU (1) AU2003208888B2 (enExample)
CA (1) CA2474011C (enExample)
DK (1) DK2311869T3 (enExample)
ES (1) ES2399503T5 (enExample)
MX (1) MXPA04007426A (enExample)
NZ (1) NZ533987A (enExample)
PT (1) PT2311869E (enExample)
WO (1) WO2003065985A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530233A (ja) * 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
WO2012001889A1 (ja) * 2010-06-28 2012-01-05 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法
JP2013031441A (ja) * 2006-12-14 2013-02-14 Merck Sharp & Dohme Corp 操作された抗ｔｓｌｐ抗体

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
ATE362534T2 (de) 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
ES2399503T5 (es) * 2002-02-01 2021-04-08 Merck Sharp & Dohme Uso de reactivos relacionados con citocinas de mamíferos
DK1651247T3 (da) * 2003-07-18 2009-01-12 Schering Corp Behandling og diagnose af neoplasmer ved anvendelse af Thymic Stromal Lymphopoietin
TR201901268T4 (tr) * 2004-03-22 2019-02-21 Mesoblast Int Sarl Mezenkimal kök hücreleri ve bunların kullanımları.
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20120124701A1 (en) 2008-02-01 2012-05-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and use thereof
US12331304B2 (en) 2008-02-01 2025-06-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and uses thereof
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
AU2010315304B2 (en) 2009-11-04 2014-03-27 Merck Sharp & Dohme Llc Engineered anti-TSLP antibody
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
JP2012032655A (ja) * 2010-07-30 2012-02-16 Fujimori Sangyo Kk ホログラム付きラミネートフィルム及びその製造方法、これを用いた容器
US20150104465A1 (en) * 2011-10-28 2015-04-16 Merck Sharp & Dohme Corp. Il-19 as a biomarker of tslp treatment
WO2013067051A1 (en) 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Biomarkers for tslp treatment
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
CU24533B1 (es) 2015-09-09 2021-07-02 Novartis Ag Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US6982320B2 (en) * 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
JP2002526079A (ja) * 1998-09-21 2002-08-20 シェーリング コーポレイション ヒトインターロイキン−ｂ５０、治療的使用
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
ATE362534T2 (de) * 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
WO2001095710A1 (en) * 2000-06-16 2001-12-20 Nakanishi, Kenji Caspase 1 gene transfer animal
PT1297017E (pt) * 2000-06-19 2012-09-04 Gen Hospital Corp Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t
AU2001271624A1 (en) * 2000-06-28 2002-01-08 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
ES2399503T5 (es) * 2002-02-01 2021-04-08 Merck Sharp & Dohme Uso de reactivos relacionados con citocinas de mamíferos

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013031441A (ja) * 2006-12-14 2013-02-14 Merck Sharp & Dohme Corp 操作された抗ｔｓｌｐ抗体
JP2010530233A (ja) * 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
WO2012001889A1 (ja) * 2010-06-28 2012-01-05 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法

Also Published As

Publication number Publication date
EP1487865A2 (en) 2004-12-22
AU2003208888B2 (en) 2006-10-19
NZ533987A (en) 2007-04-27
US20030186875A1 (en) 2003-10-02
EP2311869B2 (en) 2020-06-17
EP2311869A1 (en) 2011-04-20
US20070020262A1 (en) 2007-01-25
WO2003065985A3 (en) 2004-10-14
CA2474011A1 (en) 2003-08-14
ES2399503T3 (es) 2013-04-01
ES2399503T5 (es) 2021-04-08
JP5519946B2 (ja) 2014-06-11
EP1487865A4 (en) 2005-12-14
JP2012184259A (ja) 2012-09-27
AU2003208888A1 (en) 2003-09-02
JP2014156478A (ja) 2014-08-28
US20090017018A1 (en) 2009-01-15
EP2311869B1 (en) 2012-12-19
JP2009132730A (ja) 2009-06-18
CA2474011C (en) 2014-03-25
MXPA04007426A (es) 2004-10-11
US20110229434A1 (en) 2011-09-22
EP2077277A1 (en) 2009-07-08
US20100136003A1 (en) 2010-06-03
PT2311869E (pt) 2013-03-04
DK2311869T3 (da) 2013-03-18
WO2003065985A2 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
JP5519946B2 (ja) 哺乳動物のサイトカイン；関連する試薬の使用
Takatsu Interleukin-5 and IL-5 receptor in health and diseases
JP4638876B2 (ja) Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
US20060039910A1 (en) Methods and compositions for treating allergic inflammation
KR20220009966A (ko) 인식 분자를 포함하는 조작된 면역 세포
JP2003524644A (ja) Ｃｄ４０−結合性ａｐｃ−活性化分子
KR20070107703A (ko) 인터루킨-１７ｆ 항체 및 기타 ｉｌ-１７ｆ 신호전달안타고니스트 및 그의 용도
JP2009543579A (ja) 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
KR20070011441A (ko) Ｎｋｇ２ｄ의 조절
JP2004526413A (ja) 可溶性ｉｌ−ｔｉｆ／ｉｌ−２２レセプターまたはｉｌ−ｔｉｆ／ｉｌ−２２に結合する結合タンパク質をコードする単離された核酸分子、およびその使用
US8454955B2 (en) Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia
US20220152105A1 (en) T cell receptors and methods of use thereof
ZA200509143B (en) GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
KR20210149050A (ko) T 세포 수용체 및 이의 사용 방법
US8246959B1 (en) Dendritic cell-associated lectin-like molecules, compositions and methods of use
Deng The contribution of IL-17A and IL-17F in the pathogenesis of antibody-induced Epidermolysis Bullosa Acquisita
Pure et al. Role of Cell Adhesion Molecules in T Cell-Myocyte Interactions in Airway Inflammation.
Fu et al. Inhibition of Th2-Mediated Allergic Airway
Kastelein et al. IL-23 Production by Cosecretion of
van Wanrooij et al. Vaccination against CD99 inhibits atherogenesis in LDL receptor deficient mice
CN1798577A (zh) 使用抗－cd52抗体诱导调节性t细胞分化和/或使调节性t细胞增殖的方法以及为此使用的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090612